Current blood biomarkers are suboptimal in detecting drug‐induced liver injury (DILI) and
predicting its outcome. We sought to characterize the natural variabilty and performance …

Hepatotoxicity remains a major challenge in drug development. Although alanine
aminotransferase (ALT) remains the gold standard biomarker of liver injury, alternative biomarker …

Toxicogenomics is proposed to be a useful tool in human health risk assessment. However,
a systematic comparison of traditional risk assessment approaches with those applying …

Specific genotoxic events such as gene mutations and/or chromosome damage are considered
hallmarks of cancer. The genotoxicity testing battery enables relatively simple, rapid and …

To assess the potential of individual bile acids (IBA) and their profiles as mechanistic
biomarkers of liver injury for humans in real world situations, we interrogated samples collected …

Bile acids (BAs) have been studied as potential biomarkers of drug-induced liver injury.
However, the relationship between levels of individual BAs and specific forms of liver injury …

… Jiri Aubrecht (Pfizer, Groton, CT) presented an overview of toxicogenomic analysis of …
Aubrecht, appears promising, workshop attendees agreed that evaluation of a broader set …

Drug-induced liver injury (DILI) is a leading cause of acute liver failure and the major reason
for withdrawal of drugs from the market. Preclinical evaluation of drug candidates has failed …

Introduction: There are significant rates of attrition in drug development. A number of compounds
fail to progress past preclinical development due to limited tools that accurately monitor …

The development of in vitro molecular biomarkers to accurately predict toxicological effects
has become a priority to advance testing strategies for human health risk assessment. The …